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Androgens initiate a complex network of signals within the UGS that trigger prostate lineage
commitment and bud formation. Given its contributions to organogenesis in other systems, we
investigated a role for canonical Wnt signaling in prostate development. We developed a new method
to achieve complete deletion of beta-catenin, the transcriptional coactivator required for canonical Wnt
signaling, in early prostate development. Beta-catenin deletion abrogated canonical Wnt signaling and
yielded prostate rudiments that exhibited dramatically decreased budding and failed to adopt prostatic
identity. This requirement for canonical Wnt signaling was limited to a brief critical period during the
initial molecular phase of prostate identity speciﬁcation. Deletion of beta-catenin in the adult prostate
did not signiﬁcantly affect organ homeostasis. Collectively, these data establish that beta-catenin and
Wnt signaling play key roles in prostate lineage speciﬁcation and bud outgrowth.
& 2012 Elsevier Inc. All rights reserved.Introduction
The adult rodent prostate is an exocrine gland divided into
distinct lobes, with each lobe consisting of branching ducts and
blind ending tubules. In the embryo, this complex structure
originates from a simple cone-shaped structure called the uro-
genital sinus (UGS), which is present in both males and females
(Sugimura et al., 1986). Between embryonic days 14.5 and 17.5
(E14.5 to E17.5) in males, rising levels of testicular androgens act
directly on urogenital sinus mesenchyme to initiate prostate
development (Cunha, 1973). In particular, androgens induce a
variety of mesenchymal signals which instruct the adjacent
urogenital sinus epithelium (UGE) to adopt prostatic identity,
invade the surrounding mesenchyme, and form solid tubular
buds. Although androgens play a crucial role in initiating prostate
organogenesis from the mesenchymal compartment, the subse-
quent signaling events driving lineage commitment and branching
morphogenesis have not been fully deﬁned.
Prostate bud formation at embryonic day E17.5 represents the
ﬁrst morphologic evidence of prostate development, but molecularll rights reserved.
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ueen’s University, Kingston,evidence of prostate differentiation is present shortly after circulating
androgen levels begin to rise. The molecular phase of prostate
development is deﬁned by the earliest known marker of prostatic
differentiation, the homeobox gene Nkx3.1. Nkx3.1 expression is ﬁrst
detectable in the UGS around E16, when androgen is present but
prostate buds have yet to form (Bhatia-Gaur et al., 1999; Bieberich
et al., 1996). Although Nkx3.1 expression is a reliable marker of
prostatic differentiation, it is not required for prostate formation
(Bhatia-Gaur et al., 1999; Kim et al., 2002). This suggests that other
signaling pathways are responsible for prostate lineage commitment.
Our previous work, complemented by several other studies, have
identiﬁed Wnt pathway related genes as signiﬁcantly induced by
androgens at the initiation of prostatic differentiation (Blum et al.,
2010; Mehta et al., 2011; Schaeffer et al., 2008; Zhang et al., 2006).
Moreover, we have shown a link between the signaling pathways
active during early lineage commitment and pathways aberrantly
activated in prostate pathology. Clearly deﬁning the role for Wnt
signaling in early prostate development will provide a foundation for
future studies in prostate development, and may provide insights
into prostatic disease.
Wnt signaling is critical for cell fate determination in a variety
of organs outside of the prostate. For example, canonical Wnt
signaling is required for speciﬁcation of distal epithelial cells in the
mouse lung (Mucenski et al., 2003), and is required for the initiation
of mammary development (Chu et al., 2004). During pancreas
development, canonical Wnt signaling is required for exocrine
lineage speciﬁcation (Murtaugh et al., 2005; Wells et al., 2007).
B.W. Simons et al. / Developmental Biology 371 (2012) 246–255 247In the prostate, investigations into roles for canonicalWnt signaling in
embryonic prostate development are limited. Constitutively active
beta-catenin induces hyperplasia and prostatic intraepithelial neopla-
sia (mPIN) if expressed in the embryo (Yu et al., 2009). The non-
canonical, beta-catenin independent, Wnt pathway has been shown
to regulate bud positioning and outgrowth through examination of
Wnt5a knockout mice (Allgeier et al., 2008; Huang et al., 2009).
Postnatal manipulation of canonical Wnt signaling in organ culture of
rat UGSs inhibits branching, increases proliferation, and alters differ-
entiation of prostate epithelium (Wang et al., 2008). Investigations of
Wnt function in adult cells have shown, in addition to oncogenic
effects, that activation of canonical Wnt signaling leads to a change in
cellular differentiation, either preventing maturation or inducing
transdifferentiation into squamous epithelium (Bierie et al., 2003;
Bruxvoort et al., 2007; Yu et al., 2009). Overexpression of Wif1, an
antagonist of Wnt signaling, in recombinant tissue grafts prevents
transdifferentiation of adult bladder transitional epithelial cells to
prostate epithelial cells (Li et al., 2009). Thus, multiple lines of
evidence indicate a potential role for canonical Wnt signaling in
prostate lineage commitment, but the precise role of this pathway in
early prostate organogenesis is undeﬁned.
Canonical Wnt signaling is activated when a Wnt ligand binds a
low-density lipoprotein receptor-related protein (LRP) and one of the
frizzled (Fzd) transmembrane receptor family members (Gordon and
Nusse, 2006). These complex receptor–ligand interactions all funnel
into a single transcriptional co-activator, beta-catenin, encoded by a
single gene, Ctnnb1. Thus, deletion of Ctnnb1 can effectively silence
canonical Wnt signaling. Beta-catenin levels are strictly regulated
through an elegant series of phosphorylation and degradation events.
In the absence of Wnt ligand, cytoplasmic beta-catenin is phosphory-
lated and is subsequently ubiquitinated and targeted for proteasomal
degradation (Aberle et al., 1997; Behrens et al., 1998). Wnt signaling
inhibits phosphorylation of beta-catenin, allowing it to accumulate in
the cytoplasm and translocate to the nucleus where it associates with
TCF/LEF family transcription factors and regulates target gene expres-
sion. One such target is Axin2, a negative feedback regulator of Wnt
signaling and a useful marker of canonical pathway activity, both
generally (Jho et al., 2002) and in the prostate (Ontiveros et al., 2008).
Unlike other Wnt targets that can also be induced by other pathways,
Axin2 transcription appears to be a speciﬁc indicator of canonical Wnt
signaling (Yan et al., 2001).
Because Wnt signaling is broadly active in development,
genetic modes to explore a role for canonical Wnt signaling in
prostate lineage determination are challenging. Beta-catenin
germline knockout mice show severe defects at gastrulation
and die at E7, and thus are not useful for assessing a prostate
phenotype at E16 and later (Haegel et al., 1995). Furthermore,
existing systems for conditional deletion of genes in the prostate,
such as Nkx3.1-Cre and Probasin-Cre, are expressed after prostate
development has begun, so are unsuitable for studying lineage
commitment (Jin et al., 2003; Lin et al., 2007). We therefore
adapted a method used previously to study kidney development
(Jokela and Vainio, 2007) and accomplished controlled, conditional
deletion of beta-catenin in early prostate development (Ghosh et al.,
2011). Tamoxifen-inducible Cre allows rapid and efﬁcient deletion
of target genes ﬂanked by LoxP sites in vivo and in vitro. With this
method, we demonstrate an absolute requirement for canonical
Wnt signaling in lineage commitment and bud outgrowth.Materials and methods
Animals
All experimental procedures were approved by the Johns
Hopkins Institutional Animal Care and Use Committee (IACUC).All mouse lines were maintained on a C57BL/6J background.
Wildtype C57BL/6J, Ctnnb1ﬂ/ﬂ, NOD.SCID, and Cre-ERT1 mice
(Tamoxifen-inducible Cre inserted into Rosa26 locus) were
obtained from Jackson Laboratories (Bar Harbor, ME, Stocks 664,
4152, 1303, and 4847). Probasin-Cre (Pb-Cre4) mice were
obtained from NCI Mouse Repository (Frederick, MD). Nkx3.1-
Cre mice were a gift from Michael Shen (Columbia University,
New York, NY). For tamoxifen mediated deletion of beta-catenin,
Cre-ERT1 mice were crossed with Ctnnb1ﬂ/ﬂ mice to generate
breeder pairs homozygous for both mutant alleles. For in vivo
deletion of beta-catenin, Pb-Cre4 hemizygous, Ctnnb1ﬂ/ﬂ males
were crossed with Ctnnb1ﬂ/ﬂ females. Nkx3.1-Cre heterozygous,
Ctnnb1ﬂ/þ males were crossed with Ctnnb1ﬂ/ﬂ females to gen-
erate Nkx3.1-Cre heterozygous, Ctnnb1ﬂ/ﬂ embryos. Genotyping
was performed using primer sets and protocols recommended by
the source of each strain. DNA for PCR was isolated from tails
(adult mice) or liver (embryos).
UGS organ culture and subcapsular renal grafts
Timed pregnant female mice were obtained from overnight
mating, with the following day considered E0.5. The UGS was
harvested from embryos at the speciﬁed ages (E15.5-E17.5) and
sex was determined by gonadal inspection. UGSs were harvested
into ice-cold serum free UGS media [DMEM-F12 (1:1) media
(Invitrogen), supplemented with non-essential amino acids (Cellgro),
ITS liquid media supplement (Sigma), Penicillin/Streptomycin (Invi-
trogen), 1 g/L D-glucose (Sigma), L-glutamine (Invitrogen), and
110-8 M dihydrotestosterone (Sigma-Aldrich)]. After harvest,
UGSs were submerged in cold UGS media for 1 h containing
(Z)-4-hydroxytamoxifen (referred to in text as tamoxifen, Sigma-
Aldrich), PKF118-310, or vehicle (ethanol and DMSO, respectively).
Following treatment, the UGSs were cultured on 0.4 mmmembranes
(Millipore), oriented with the ventral surface up, overlying UGS
media containing the indicated drugs or vehicle for 2–5 day. Media
was changed every 48 h. In all experiments, a minimum of 5 UGSs
were treated per condition. For subcapsular renal grafts, UGSs and
prostates were similarly harvested and cultured for 48 h in the
presence of tamoxifen or vehicle, then grafted under the kidney
capsule of adult male NOD.SCID host mice and harvested after
4 weeks.
Histology, immunohistochemistry (IHC), and immunoﬂuorescence
Tissues were ﬁxed in formalin, routinely processed, embedded,
and sectioned. For immunohistochemistry, the sections were
deparafﬁnized and rehydrated before steaming in Target Retrieval
Solution (Dako) for 40 min. For Nkx3.1 staining, slides were
steamed for 40 min in EDTA pH 9. Endogenous peroxidases were
quenched by peroxide treatment, and the slides were blocked for
1 h with Serum Free Protein Block (Dako). Slides were incubated
with antibodies directed against beta-catenin (BD Biosciences,
#14), E-cadherin (Cell Signaling, #4065), AR (Santa Cruz, N-20),
FoxA2 (Cell Signaling, D56D6), Nkx3.1 (Chen and Bieberich, 2005),
or Hoxb13 (McMullin et al., 2009), and visualized with ImmPRESS
Polymer detection kit (Vector Labs). For two color immunohis-
tochemistry, the procedure was repeated and visualized with
Vector VIP Peroxidase Substrate. For immunoﬂuorescence, Alexaﬂuor
conjugated secondary antibodies (Invitrogen) were applied after
incubation with the primary antibody.
Real-time reverse-transcription PCR
To separate UGE and UGM, the UGSs were incubated in
1% Trypsin for 75 min and tissue compartments were separated
by ﬁne dissection as previously described (Staack et al., 2003).
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strand cDNA was synthesized using Ready-To-Go You-Prime
First-Strand Beads (GE Healthcare) according to manufacturer’s
directions. Quantitative real-time PCR was performed using Fast
SYBR Green Master Mix (Applied Biosystems) with oligonucleo-
tides speciﬁc for Hprt, Ctnnb1, Axin2, Nkx3.1, Ar, Cdh1, Fgf10, Tcf7,
Foxa1, and Foxa2 (sequences listed in Supplementary Table S1).
Individual expression values were normalized by comparison to
Hprt, and relative levels of mRNA expression were calculated
using the delta–delta Ct method (Livak and Schmittgen, 2001).
Immunoblotting
UGSs were lysed in NuPAGE LDS sample buffer and were
fractionated on NuPAGE gels (Invitrogen). After transfer to PVDF
membranes, the samples were blocked and incubated with
antibodies directed against beta-catenin (BD Biosciences, #14)
and GAPDH (Santa Cruz, Clone 6C5). Blots were developed using
Odyssey IRDye (LI-COR Biosciences).Results
Temporal and spatial pattern of Wnt signaling in the UGS
Multiple components of the Wnt pathway are induced by
androgens in a temporal and spatial pattern that suggests a role
for Wnt signaling in early prostate development (Blum et al.,
2010; Mehta et al., 2011; Schaeffer et al., 2008; Zhang et al.,
2006). To understand the relationship between Wnt signaling and
prostate lineage speciﬁcation, we measured the relative expres-
sion of Axin2 and Nkx3.1 mRNA. UGSs were harvested at E16.5
from male and female embryos and mRNA was isolated from
enzymatically separated UGM and UGE. At this time point of
prostate lineage speciﬁcation, when molecular prostatic differ-
entiation subsequent to androgen exposure is beginning but
morphologic changes have not begun, Axin2 transcript expression
was signiﬁcantly higher in males than in females. Furthermore,
differential expression was limited to the UGE (Fig. 1A), suggest-
ing a role for Wnt in specifying the prostate epithelial lineage.
To reﬁne the timing of these events, we cultured androgen-naive
E15.5 UGSs with dihydrotestosterone (DHT), a potent androgen
capable of inducing prostatic differentiation in vitro (Lasnitzki and
Mizuno, 1977), and harvested UGE after 24 and 48 h of androgen
exposure. Compared to controls harvested before culture, UGE
showed signiﬁcantly increased Axin2 transcript expression at both
time points after androgen exposure, coincident with increasedFig. 1. Androgen induces Wnt signaling in UGE during prostate speciﬁcation. (A) qRT-PCR o
to respective female samples. Differential expression of Axin2 was limited to the UG
signiﬁcant increase in Axin2 expression at 24 and 48 h (po0.01) by qRT-PCR of separate
represent mean7standard error of the mean (SEM), p-values calculated using the unpNkx3.1 expression (Fig. 1B). Together, these observations conﬁrm
that canonical Wnt/beta-catenin signaling is active in UGE during
the earliest phases of prostate lineage speciﬁcation, including
time points before the emergence of prostate buds.
Conditional deletion of beta-catenin in the UGS
Because germline deletion of beta-catenin is embryonic lethal,
we used a conditional Cre-LoxP system to delete Ctnnb1, the gene
encoding beta-catenin. E15.5 UGSs from embryos homozygous for
tamoxifen-inducible Cre (CreERT1) and ﬂoxed beta-catenin
(Ctnnb1ﬂ/ﬂ) were cultured with 2 mM tamoxifen or vehicle for
48 h, and immunoblots were used to determine the time course
and efﬁciency of gene deletion (Badea et al., 2003; Brault et al.,
2001). Beta-catenin protein levels began to decrease within 24 h
of tamoxifen exposure and were nearly undetectable by the 48 h
time point (Fig. 2A). As expected, canonical Wnt signaling was
dramatically suppressed after beta-catenin deletion, indicated by
marked reduction in Axin2 and Tcf7 mRNA extracted from whole
UGS cultures 48 h after tamoxifen exposure (Fig. 2C). Several
other genes known to inﬂuence prostate development were
unaffected by beta-catenin loss, including the beta-catenin bind-
ing partner E-cadherin (Cdh1) and known mediators of prostate
development, such as androgen receptor (Ar), Fgf10, and Foxa1
(Fig. 2C). In contrast, expression of the transcription factor Foxa2,
which has been shown to be induced by activated beta-catenin in
the prostate (Yu et al., 2011; Yu et al., 2009), was suppressed in
the gene-deleted UGS compared to controls. Immunohistochem-
istry (IHC) conﬁrmed uniform deletion of beta-catenin through-
out the UGS and a marked decrease in FoxA2 expression (Fig. 2B).
In the control group, FoxA2 expression closely matched Nkx3.1
expression at the UGE/UGM border and in the nascent buds. After
beta-catenin deletion, Nkx3.1 was undetectable, and FoxA2
expression was limited to scattered individual cells. Androgen
receptor, which is expressed throughout the UGS in both sexes
before prostate development, continued to be expressed in both
the UGE and UGM of beta-catenin deleted UGSs (Fig. 2B).
Loss of Wnt signaling prevents bud formation and prostate
determination
In a well established in vitro organ culture system (Doles et al.,
2005), wild type controls showed robust bud development,
whereas tamoxifen-treated beta-catenin null UGSs showed little
or no bud formation (Fig. 3A, B). To conﬁrm that decreased
budding was due to loss of canonical Wnt signaling and not a
peripheral role of beta-catenin, we treated UGSs with the smallf male and female E16.5 separated UGE and UGM for Axin2 expression normalized
E (po0.01). (B) E15.5 female UGSs cultured in vitro with DHT demonstrated a
d UGE, coinciding with signiﬁcant increases in Nkx3.1 expression (po0.01). Graphs
aired two-tailed Student’s t-test with unequal variance.
Fig. 2. Inducible knockout of beta-catenin is rapid and results in decreased Foxa2 expression. (A) Immunoblot analysis of E15.5 CreERT1 Ctnnbﬂ/ﬂ UGSs grown in vitrowith 2 mM
tamoxifen showed decreased beta-catenin protein level after 24 h and loss within 48 h. (B) H&E stain and IHC conﬁrmation of beta-catenin deletion after 48 h tamoxifen
treatment (scale bar 100 mm). Nkx3.1 expression is undetectable, and FoxA2 expression is limited to scattered individual cells (arrows and inset). AR expression was
similar between the two groups. Scale bars are 100 mm and (C) qRT-PCR analysis of whole UGSs after 48 h tamoxifen treatment demonstrates decreased beta-catenin
(Ctnnb1), Axin2, Tcf7, and Foxa2 expression relative to vehicle treated controls (po0.01). Graph represents mean7standard error of the mean (SEM), p-values calculated
using the unpaired two-tailed Student’s t-test with unequal variance.
Fig. 3. Deletion of beta-catenin prevents prostate differentiation and bud formation in vitro. (A) Wildtype (left column) and CreERT1 Ctnnb1ﬂ/ﬂ (right column) E15.5 UGSs
cultured in vitro for ﬁve days with 2 mM tamoxifen, vehicle, or 20 nM PKF118-310 and (B) Quantitative analysis of bud formation in vitro demonstrates signiﬁcantly
reduced bud formation in beta-catenin deleted and inhibitor treated tissues compared to controls (n¼5, po0.01), but no difference in tamoxifen-treated versus vehicle
treated wildtype UGSs (n¼5, p¼0.663). Graph represents mean7standard error of the mean (SEM), p-values calculated using the unpaired two-tailed Student’s t-test with
unequal variance.
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catenin/TCF complex to disrupt Wnt signaling (Lepourcelet et al.,
2004). We observed a similar phenotype with both genetic andpharmacologic methods of Wnt inhibition, with signiﬁcant
decreases in bud number in both beta-catenin deleted and
PKF118-310 treated UGSs compared to controls (Fig. 3A, B).
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tamoxifen, the dose used for conditional deletion of beta-catenin,
nor a log fold higher dose had any discernable effect on bud
formation or growth (Fig. 3A, S1), indicating the observed effect is
not from tamoxifen exposure, but loss of beta-catenin.
Several steps are required for prostate bud formation, most
notably lineage commitment, followed by bud initiation and bud
elongation (Bhatia-Gaur et al., 1999). We investigated the acqui-
sition of prostate identity using immunohistochemistry for the
prostate epithelial lineage marker Nkx3.1. Expression of Nkx3.1 by
immunohistochemistry was similar in control UGSs grown in vitro
or in vivo, but beta-catenin deleted UGSs failed to express Nkx3.1,
suggesting a failure of prostate lineage commitment (Fig. 2B).
Beta-catenin deletion prevents prostate development
Growth of UGSs as subcapsular renal grafts mirrors normal
development in vivo, allowing assessment of long term prostate
growth and maturation (Doles et al., 2005). After four weeks of
growth in a host mouse, tamoxifen-treated grafts were signiﬁ-
cantly smaller than vehicle-treated controls (Fig. 4A, H, and S2).
Histology and immunohistochemical analysis showed the control
grafts to be composed primarily of mature prostate ducts
(Fig. 4B–G). The prostatic epithelium in these grafts expressed
normal levels of beta-catenin, Nkx3.1, Hoxb13, and AR (Fig. 4D–G).
The grafts from beta-catenin deleted UGSs were examined by two
experienced pathologists (BWS, DMB) for histologic evidence of
prostatic differentiation. The grafts were found to be disorga-
nized, and did not contain histologically recognizable seminal
vesicle or prostatic structures (Fig. 4I, J, and S3). Immunohisto-
chemistry showed a complete absence of beta-catenin and Nkx3.1
expression in the tamoxifen-treated and grafted UGSs (Fig. 4K, L),
conﬁrming a lack of prostate differentiation. Although Nkx3.1 is a
robust marker of prostate lineage, its expression is regulated by
androgens (Sciavolino et al., 1997). An androgen-independent
marker of prostate identity can be found in Hoxb13. Although it
is more widely expressed in the developing embryo, expression in
adult tissues is limited to colon and prostate (Sreenath et al.,
1999). All grafted tissues remained AR positive (Fig. 4N), butFig. 4. Beta-catenin knockout grafts do not show prostatic differentiation. Renal grafts from
or tamoxifen (H–N) before 4 weeks growth as subcapsular renal grafts. Vehicle treated
Nkx3.1 (E), Hoxb13 (F), and AR (G). Beta-catenin deletion resulted in smaller grafts
without recognizable prostatic differentiation (I, J). IHC analysis showed loss of beta-ca
(M), with expression limited to small foci of cells with periurethral gland differentiati
others 50 mm.Hoxb13 expression was limited to scattered cells within areas of
periurethral gland differentiation (Fig. 4M). The lack of signiﬁcant
prostate differentiation and failure of bud formation conﬁrmed
that canonical Wnt/beta-catenin signaling is required for prostate
lineage speciﬁcation.
After lineage commitment, prostate development can occur
without beta-catenin.
To determine if canonical Wnt signaling is continuously required
for prostate lineage commitment or if it is only required during
prostatic differentiation, we utilized methods to delete beta-catenin
at time points after lineage commitment and bud initiation. The
Nkx3.1-Cre mouse has been indispensible for studies of prostatic
development and differentiation, but reporter-based studies of Cre
activity show expression after E17.0 (Lin et al., 2007), and expression
of ﬂoxed target genes may not be eliminated until after E18.5
(Thomsen et al., 2008). We took advantage of this Cre expression
timeline and compared deletion with our inducible system, giving
loss of beta-catenin within 24–48 h, to Nkx3.1-Cre Ctnnb1ﬂ/ﬂ tissues,
predicted to show complete deletion at a later time point. The
Nkx3.1-Cre cross was embryonic lethal, possibly due to expression
in the developing sclerotome (Stanfel et al., 2006; Thomsen et al.,
2008), but we were able to harvest E15.5 UGSs and culture them
in vitro. In contrast to the inducible system, these UGSs were able to
show evidence of prostatic differentiation by forming buds which
lacked beta-catenin, but expressed Nkx3.1 (Fig. 5).
To further assess the timeline of beta-catenin dependent
prostate differentiation, we allowed prostate development to
proceed in vivo until birth, and harvested prostates from pups at
postnatal day zero (P0), approximately ﬁve days after prostate
development begins. These prostates were treated with vehicle or
tamoxifen in vitro for two days to delete beta-catenin, and grown
for four weeks as subcapsular renal grafts. When harvested,
control grafts contained mature prostate tissue (Fig. 6A–D).
Tamoxifen-treated grafts showed scattered areas of prostatic
differentiation and Nkx3.1 expression despite complete beta-
catenin deletion (Fig. 6E–H). In addition to Nkx3.1, these grafts
expressed basal and luminal markers (CK14, p63, CK8) in the
expected pattern (Fig. S5). However, the SMA positive stroma was
frequently discontinuous around the beta-catenin deleted glands.E15.5 CreERT1 Ctnnb1ﬂ/ﬂ UGSs grown after 48 h in vitro culture with vehicle (A–G)
grafts show normal prostate gland formation (B, C), and express beta-catenin (D),
compared to controls (A, H), and H&E staining demonstrates disorganized grafts
tenin (K), and Nkx3.1 (L). Hoxb13 expression was absent in the majority of tissue
on (inset). Grafted tissue retains AR expression (N). Scale bars 500 mm in B, I. All
Fig. 5. Beta-catenin deletion after differentiation does not prevent bud formation. Organ cultures of E15.5 Nkx3.1-Cre Ctnnb1ﬂ/þ and Ctnnb1ﬂ/ﬂ UGSs show normal beta-
catenin (A) and Nkx3.1 (C) expression in control UGS prostate buds after 5 days in controls. Nkx3.1-Cre Ctnnb1ﬂ/ﬂ mice form (B) beta-catenin deﬁcient prostate buds that
(D) maintain Nkx3.1 expression. Scale bars are 50 mm.
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signaling, we harvested E15.5 female UGSs for culture with DHT
for 24 h to initiate prostatic differentiation before deleting beta-
catenin with tamoxifen. Grown in vitro, UGSs harvested from
male or female embryos at E15.5 show an absence of budding
after beta-catenin deletion (Fig. S4). However, pretreatment of
these grafts with DHT for 24 h before tamoxifen treatment, or
physiologic in vivo exposure to DHT in male embryos harvested at
E16.5, resulted in rudimentary bud formation despite beta-
catenin deletion (Fig. S4). Grafts from these E15.5 UGSs pretreated
with DHT before tamoxifen treatment contained occasional
mature prostate glands which maintained Nkx3.1 expression
despite the absence of beta-catenin (Fig. 6I–L). Thus, these results
indicate a window between E14.5-E16.5 where prostatic differ-
entiation requires canonical Wnt/beta-catenin signaling (Fig. 6M).
Loss of beta-catenin in luminal adult epithelial cells does not affect
glandular homeostasis
In addition to roles in canonical Wnt signaling, beta-catenin
participates in adherens junctions by binding E-cadherin and may
play a role in androgen signaling through interactions with AR
(Aberle et al., 1996; Truica et al., 2000). We sought to exclude
the possibility that loss of beta-catenin would interfere withE-cadherin localization or androgen signaling. To accomplish this,
we examined the prostates from 12 week old Probasin-Cre
(Pb-Cre4) Ctnnb1ﬂ/ﬂ mice. Probasin-driven Cre expression is initiated
postnatally, is active in the luminal epithelial cells, and should
have no effect on prostate determination and initial branching.
Because Probasin-Cre shows mosaic expression in the prostate,
we were able to compare beta-catenin deleted and replete cells in
the same gland. Both cell types showed normal histology and
expression of E-cadherin and AR. Expression of the androgen-
independent differentiation marker Hoxb13 was unchanged, as
was the androgen-dependent Nkx3.1 (Fig. 7A–D). These data
indicate that loss of beta-catenin in adult prostate cells does not
signiﬁcantly affect homeostasis and suggest that androgen signal-
ing and cellular adhesion sufﬁcient to maintain mature prostate
glands can occur in the absence of beta-catenin.Discussion
A variety of Wnt pathway members have been shown to be
expressed in the developing prostate in an androgen dependent
fashion. However, the role of canonical Wnt signaling in early
prostate development was not previously addressed. Here, we
show that prostate lineage speciﬁcation depends on canonical
Fig. 6. After androgen action, prostate glands can form without beta-catenin. Grafts from P0 CreERT1 Ctnnb1ﬂ/ﬂ prostates treated in vitro with vehicle (A–D) or tamoxifen
(E–H) for 48 h show normal development in controls (A–D). Tamoxifen-treated grafts are smaller than controls, but show prostate gland formation (E,F) despite loss of
beta-catenin (G), and retain Nkx3.1 expression (H). Grafts from E15.5 female UGSs pretreated with DHT for 24 h before exposure to tamoxifen (I–L) show a small number
of prostate glands (I, J) forming without beta-catenin (K) that retain Nkx3.1 expression (L). (M) Timeline depicting normal prostatic differentiation, bud formation, and the
transient requirement for Wnt signaling on which these processes rely. Scale bars 500 mm in A, E and I. All others 50 mm.
B.W. Simons et al. / Developmental Biology 371 (2012) 246–255252Wnt signaling through beta-catenin, and that this signal is required
at the earliest stages of prostate lineage commitment. Deletion of
beta-catenin or pharmacologic inhibition of canonical Wnt signal-
ing blocks prostatic differentiation, as illustrated by a failure to
initiate bud formation or form recognizable glandular tissue, and
by undetectable levels of Nkx3.1 and greatly reduced Hoxb13
expression. Previous reports indicate a role for beta-catenin in
epithelial differentiation and cell fate determination in other
organs (Chu et al., 2004; Mucenski et al., 2003; Murtaugh et al.,
2005; Wells et al., 2007). Our ﬁndings are consistent with these
reports, and suggest that Wnt mediated cell-fate determination
may be a widely conserved feature of branching morphogenesis.
Investigations into the genetic programs which control prostate
morphogenesis are limited by available strategies for conditional
mutagenesis. Germline knockouts and other mutant mice have
proven useful for studying some pathways, but certain mutations
result in early embryonic death or prevent normal formation of the
UGS. Currently available models for conditional mutagenesis, suchas Cre-LoxP systems, are useful for studies of late embryonic
prostate morphogenesis and adult homeostasis, but are activated
too late in development to study the initial stages of prostate
differentiation. We show that conditional deletion of genes in the
developing prostate can be accomplished rapidly and efﬁciently
with complete temporal control.
In addition to its role in canonical Wnt signaling, beta-catenin
functions in cell–cell adhesion though participation in the adhe-
rens junction. In the prostate, loss of beta-catenin did not effect
on E-cadherin expression or localization, and previous reports
show no interruption of adherens junctions and cell–cell adhesion
after loss of beta-catenin (Bridgewater et al., 2008). A pharmaco-
logic inhibitor of Wnt signaling produced similar results to
genetic deletion. Since the inhibitor affects transcriptional activity
of beta-catenin through disruption of its association with Tcf/LEF
family members, it should not affect adherens functions of beta-
catenin. This result further supports the requirement for canonical
Wnt signaling in prostate speciﬁcation.
Fig. 7. Mature secretory luminal cells maintain prostatic identity after beta-catenin deletion. Pb-Cre4 Ctnnb1ﬂ/ﬂ mice show mosaic deletion of beta-catenin in luminal prostate
epithelial cells. In areas with beta-catenin expression (arrow) and in areas of beta-catenin deletion (arrowhead) epithelial cells retain normal expression and localization of
E-cadherin (A) and Androgen receptor (B) by immunoﬂuorescence. (C, D) Two color immunohistochemistry shows mosaic beta-catenin expression (purple) and normal
expression of Hoxb13 (C), and Nkx3.1 (D) in brown. Scale bars are 50 mm.
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include postnatal regulation of branching and stem cell main-
tenance (Ontiveros et al., 2008; Wang et al., 2008). Our ﬁndings
do not contradict these reports, as we focused on the role of
canonical Wnt signaling in earlier prenatal events. Prostate tissue
forming from beta-catenin deleted tissue was smaller than con-
trols, but because we used in vitro organ culture and subcapsular
renal grafts, we were unable to enumerate branch points. We
cannot make determinations about the role of Wnt signaling in
prostatic stem cell maintenance because many of these pheno-
types are evident only after castration and regeneration cycling of
adult mice. Just as we have shown a short window of absolute
requirement for canonical Wnt signaling in early prostate devel-
opment, it is reasonable to hypothesize that the function of the
Wnt signaling pathway can change during different phases of
prostate maturation.
Prostate development is controlled by androgens, but estrogen
and estrogenic endocrine disruptors have shown a variety of
effects on prostate growth and branching prostate (Prins et al.,
2001). By using an inducible system for gene deletion that
requires the presence of tamoxifen, a partial agonist of the
estrogen receptor in mice, we were compelled to carefully control
for potential effects of tamoxifen on prostate lineage speciﬁcation
and branching. Fortunately, no observable effects of tamoxifen on
UGS organ culture were noted, even at one log higher concentra-
tion than those necessary to induce Cre recombination.
Androgen induced signals from the UGM to the UGE initiate
prostate development (Cunha, 1973). So called ‘‘andromedins’’ are
postulated to relay this signal and induce prostatic differentiation.
A number of Wnt family members are expressed in the UGS in a
manner consistent with a role in epithelial–mesenchymal interac-
tions during prostate induction, and could function as andromedins
(Mehta et al., 2011; Schaeffer et al., 2008; Zhang et al., 2006). Herewe show that canonical Wnt signaling in the epithelium is induced
after androgen exposure. Although we have determined that
canonical Wnt signaling is required for prostate speciﬁcation, the
source and identity of the initiating Wnt ligand has yet to be
determined. Because this inducible system deletes beta-catenin in
both the epithelium and mesenchyme, we could not determine
which compartment requires Wnt signaling. Although Nkx3.1-Cre
expression is speciﬁc to the epithelium, the ability of prostatic
differentiation to occur after Nkx3.1-Cre mediated deletion of beta-
catenin suggests that either the Wnt requirement is mesenchymal,
or, as we hypothesize, that the requirement is epithelial, but
transient, and abates prior to Nkx3.1-Cre expression. While it
remains unclear whether UGE or UGM initiates Wnt signaling,
we detect androgen induced Wnt signaling exclusively in the UGE.
An additional aspect of this pathway which remains undeter-
mined is the precise role of Wnt/beta-catenin signaling in prostate
lineage commitment, and the downstream mediators that carry
out this role. In our study, the absence of identiﬁable prostatic
structures in beta-catenin null tissue indicates an absolute require-
ment for this protein in prostatic induction. However, it is unclear
if Wnt signaling is directly inducing prostatic lineage committ-
ment, or if it plays another, more permissive role, such as promot-
ing survival or proliferation of committed prostate progenitors.
A key to determining the function of Wnt signaling will be
determining the downstream targets which are subsequently
induced. Previous studies have indicated that Foxa2 is positively
regulated by activated Wnt signaling (Yu et al., 2011; Yu et al.,
2009). Here we show the complement, that Foxa2 expression is
diminished after beta-catenin deletion. The timing and localization
of Foxa2 during prostate development, expression only during early
morphogenesis, suggest it may play a role in the earliest stages of
prostate lineage commitment. Our data conﬁrm that Foxa2 is
regulated by Wnt signaling, suggesting a potential pathway which
B.W. Simons et al. / Developmental Biology 371 (2012) 246–255254could mediate the transient requirement for Wnt signaling in
prostate development.
In summary, we show a critical requirement for canonical
Wnt/beta-catenin signaling in early prostate lineage commitment.
To accomplish this, we adapted a strategy for gene deletion to use
in studies of prostatic differentiation and development that allows
careful interrogation of gene function at the earliest stages of
prostate development. Future studies should focus on the identity
and source of the signaling molecules that initiate Wnt signaling in
the UGE, and what downstream targets mediate this effect.Acknowledgments
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